Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure

Figure 1 Histology of tissue sample for chronic hepatitis B and and acute-on-chronic liver failure in representative patients. A: Chronic hepatitis B (CHB, mild): Mild enlarged portal tract is infiltrated by lymphocytes without interface hepatitis. Spot necrosis is in the lobule (left, HE, × 100). Portal tract shows mild fibrosis (right, Masson trichrome); B: Acute-on-chronic liver failure (ACLF): Massive necrosis of parenchyma with cirrhotic nodule remaining (left, HE, × 100). Cirrhotic nodule is surrounded by fibrous tissue (arrow) (right, Masson trichrome).

Figure 2 Serum M65, M30 levels and M30/M65 ratio can significantly identify healthy control, chronic hepatitis B and acute-on-chronic liver failure. A: Serum M65 levels can significantly indentify healthy control, chronic hepatitis B (CHB) and acute-on-chronic liver failure (ACLF); B: Serum M30 levels can significantly indentify healthy control, CHB and ACLF; C: The ratio of M30/M65 can significantly identify healthy control, CHB and ACLF. The length of the box represents the interquartile range. The line through the middle of the box is the median. The whiskers indicate the minimum and maximum values.

Figure 3 Both serum M65 and M30 levels show diagnostic performance to identify acute-on-chronic liver failure patients in cohort patients. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; CHB: Chronic hepatitis B; ACLF: Acute-on-chronic liver failure; AUC: Area under the curve.

Figure 4 Comparison of the prognostic values of Model for End-Stage Liver Disease, Child-Pugh score and the ratio of M30/M65 in acute-on-chronic liver failure patients. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; MELD: Model for End-Stage Liver Disease; AUC: Area under the curve.